Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | CALCA | P06881 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134076 | 0.92 | TLR8 (0.42) | TLR8ADORA2AADORA1TP53NLRP3 | |
| SCHEMBL6134709 | 0.91 | ADORA2A (0.38) | TLR8ADORA2AADORA1TP53CALCA | |
| SCHEMBL6133911 | 0.90 | NLRP3 (0.45) | TLR8ADORA2AADORA1TP53NLRP3 | |
| SCHEMBL6134535 | 0.89 | TLR8 (0.41) | TLR8ADORA2AADORA1TP53POLB | |
| SCHEMBL6134030 | 0.89 | CALCA (0.43) | TLR8ADORA2AADORA1CALCA | |
| SCHEMBL6133703 | 0.88 | GHSR (0.41) | ADORA2AADORA1TP53ADORA3 | |
| SCHEMBL6135237 | 0.86 | ADORA2A (0.42) | ADORA2AADORA1TP53POLB | |
| SCHEMBL6133674 | 0.86 | KDM4E (0.38) | ADORA2AADORA1TP53POLB | |
| SCHEMBL6134892 | 0.86 | TP53 (0.39) | ADORA2AADORA1TP53POLB | |
| SCHEMBL6133705 | 0.85 | ADORA2A (0.41) | ADORA2AADORA1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | TLR8 4293/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.